NCT Number: NCT01932866
Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence
The purpose of this randomized, controlled study is to evaluate whether the knowledge of a personalized diabetes risk score affects adherence to a 12-week diet and exercise lifestyle change program in prediabetic patients. The intervention group will receive diabetes risk score results at the beginning of the twelve weeks, and the control group will not receive these results. Both groups will review their baseline and 12-week diabetes risk score results at the conclusion of the program and will be followed for an additional twelve weeks. Attendance rates and changes in weight, BMI, abdominal circumference, blood pressure, HgA1c, fasting blood glucose, cholesterol, and diabetes risk score will be compared between the groups.
Looking for future studies?
Notify MeKey information
Conditions
Age range
30 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
David Grant Medical Center, Travis AFB, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Men and women of all ethnic groups
- ≥30 -75 years of age
- Pre-diabetic defined as follows: fasting plasma glucose (FPG) 100-125mg/dL, HbA1c 5.7% to 6.4%.
- Body Mass Index ≥ 25 kg/m2
- Tricare beneficiary
Exclusion criteria
Diagnosis of type 1 or type 2 diabetes mellitus (defined as FPG ≥126 mg/dl on two different occasions or random blood sugar ≥200) If fasting glucose >= 126 only once, a second lab does not need to be arranged in an attempt to diagnose diabetes. It is acceptable for the patient to proceed in the trial. Also, Tethys lab results (e.g., fasting glucose and A1C) should not be used to make decisions about including or excluding patients in the trial. Only Air Force lab results should be used to make this determination.
- Active duty military members
- Patients with untreated hypothyroidism or previously diagnosed Cushing's syndrome
- Subjects previously treated with metformin or thiazolidinediones in the previous 12 months
- Psychological or physical disabilities deemed likely to interfere with participation in the study
- Patients currently using weight-loss medications or medications known to affect body weight (i.e. chronic corticosteroid use)
- Major medical conditions that prevent participation in the Group Lifestyle Balance Prevention Program (i.e. severe cardiovascular or cerebrovascular disease, severe renal or liver dysfunction, etc.)
- Concurrent participation in a different weight loss program
- Previous bariatric surgery
- Unwilling to agree with the study assignments or provide informed consent
- Participation in any other research project that would interfere with this protocol
- Unable to read and write English
- Pregnant or nursing patients
- Female patients unwilling to undergo a pregnancy test or report possible pregnancy promptly and unwilling to take precautions to avoid pregnancy if potentially fertile during the study course
Discontinuation Criteria:
- Consent is withdrawn
- Death occurs
- A woman becomes pregnant
- Severe impairment of manual dexterity, vision, or intellectual function
- They become lost to follow-up because of a move or transfer outside of the geographic area
Treatment and study plan
Primary outcomes
-
Attendance rates
Time frame: 6 months
Attendance rates (percentage of subjects attending the classes) of the two groups will be compared.
-
Change in weight
Time frame: baseline, 12 weeks, 24 weeks
change in weight from baseline to 12 weeks and 24 weeks will be compared between groups.
-
Change in BMI
Time frame: baseline, 12 weeks, 24 weeks
change in BMI from baseline to 12 weeks and 24 weeks will be compared between groups.
-
Change in abdominal circumference
Time frame: baseline, 12 weeks, 24 weeks
change in abdominal circumference from baseline to 12 weeks and 24 weeks will be compared between groups.
Secondary outcomes
-
Change in blood pressure
Time frame: baseline, 12 weeks, 24 weeks
change in blood pressure from baseline to 12 weeks and 24 weeks will be compared between groups.
-
Change in HgA1c
Time frame: baseline, 12 weeks, 24 weeks
change in HgA1c from baseline to 12 weeks and 24 weeks will be compared between groups.
-
Change in fasting blood glucose
Time frame: baseline, 12 weeks, 24 weeks
change in fasting blood glucose from baseline to 12 weeks and 24 weeks will be compared between groups.
-
Change in cholesterol
Time frame: baseline, 12 weeks, 24 weeks
change in cholesterol from baseline to 12 weeks and 24 weeks will be compared between groups.
-
Change in diabetes risk score
Time frame: baseline, 12 weeks, and 24 weeks
change in diabetes risk score from baseline to 12 weeks and 24 weeks will be compared between groups.
Sponsors and collaborators
Lead sponsor
59th Medical Wing
Fed
Registry information
Official study title
Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence (IDEA Trial)
Acronym: IDEA
Important dates
- Study start
- 2010
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Aug 30, 2013
- Registry last updated
- Aug 30, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
The Influence of Time-Restricted Eating in Patients With Metabolic Syndrome
NCT04057339
Behavior, Fasting
La Jolla, California, United States
View Trial DetailsSkeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans
NCT03077360
Body Weight, Diabetes Mellitus
Aurora, Colorado, United States
View Trial DetailsPhentermine/Topiramate for Uric Acid Stones
NCT04621929
Body Weight, Glucose Intolerance
Gainesville, Florida, United States
View Trial DetailsTime Restricted Eating on Cancer Risk
NCT05038137
Behavior, Breast Cancer
Charleston, South Carolina, United States
View Trial Details